Editas Medicine Announces U.S. Patent Office Ruling in Favor of Broad Institute in CRISPR/Cas9 Dispute

Editas Medicine's U.S. patent and trademark office reaffirmed the PTAB's decision favoring the Broad Institute in a CRISPR/Cas9 interference case. The decision affirms Broad's inventorship priority for gene editing in eukaryotic cells, including human cells. Editas Medicine retains the right to appeal to the CAFC. The CRISPR/Cas9 patents at issue are exclusively licensed to Editas Medicine for developing and commercializing CRISPR/Cas9-based medicines.